author-photo

Francesco Atzori

Autonomous University of Barcelona

6

Papers

952

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters?

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

2011 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (99)
Status of PI3K inhibition and biomarker development in cancer therapeutics

2010 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (136)
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, PreventsPI3K Signaling and Inhibitsthe Growth of Cancer Cellswith Activating PI3K Mutations

2008
Show All
- Source
- Cite
- Save
Citations (0)
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

2008 Cancer Research
Show All
- Source
- Cite
- Save
Citations (664)
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (52)